Skip to main content
Erschienen in: Clinical Research in Cardiology 10/2012

01.10.2012 | Original Paper

Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block

verfasst von: Brigitte Lampe, Christoph Hammerstingl, Jörg Otto Schwab, Fritz Mellert, Birgit Stoffel-Wagner, Andreas Grigull, Rolf Fimmers, Bernhard Maisch, Georg Nickenig, Thorsten Lewalter, Alexander Yang

Erschienen in: Clinical Research in Cardiology | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The impact of atrial fibrillation (AF) on heart failure (HF) was evaluated in patients with preserved left ventricular (LV) function and long-term right ventricular (RV) pacing for complete heart block.

Methods

Clinical, echocardiographic, and laboratory parameters of HF were assessed in 35 patients with established AF who had undergone ablation of the atrioventricular node and pacemaker implantation (Group A) and 31 patients who received dual-chamber pacing for spontaneous complete heart block (Group B).

Results

During a follow-up period of 12.7 ± 7.5 years, New York Heart Association (NYHA) functional class increased from 1.3 ± 0.5 to 2.1 ± 0.6 (p < 0.0001) in Group A, and from 1.3 ± 0.4 to 1.6 ± 0.7 (p < 0.01) in Group B. Left ventricular ejection fraction (LVEF) decreased from 59.7 ± 5.1 to 53.0 ± 8.2 (p < 0.0001) in Group A, but remained stable (58.6 ± 4.2 vs. 56.9 ± 7.0 %, p = 0,21) in Group B. At the end of follow-up, markers of LV function were moderately depressed in Group A compared with those in Group B: NYHA class 2.1 ± 0.6 versus 1.6 ± 0.7, p = 0.001; LVEF 53.0 ± 8.2 versus 56.9 ± 7.0 %, p < 0.05; LV diastolic diameter 53.6 ± 5.8 mm versus 50.7 ± 4.9 mm, p < 0.05; N-terminal pro-brain natriuretic peptide (NT-proBNP) 1116.8 ± 883.9 versus 622.9 ± 1059.4 pg/ml, p < 0.05. Progression of paroxysmal AF to permanent AF during follow-up was common, while new onset of AF was rare. Permanent AF was an independent predictor of declining LVEF >10 %, increasing NYHA class ≥1, and NT-proBNP levels >1,000 pg/ml.

Conclusions

Permanent AF was associated with adverse effects on LV function and symptoms of HF in patients with long-term RV pacing for complete heart block, and appears to play an important role in the development of HF in this specific patient cohort.
Literatur
1.
Zurück zum Zitat Scheinman MM, Morady F, Hess DS, Gonzalez R (1982) Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmia. JAMA 248:851–855PubMedCrossRef Scheinman MM, Morady F, Hess DS, Gonzalez R (1982) Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmia. JAMA 248:851–855PubMedCrossRef
2.
Zurück zum Zitat Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420PubMedCrossRef Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420PubMedCrossRef
3.
Zurück zum Zitat Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S (1997) Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 96:2617–2624PubMedCrossRef Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S (1997) Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 96:2617–2624PubMedCrossRef
4.
Zurück zum Zitat Takahashi Y, Yoshito I, Takahashi A, Harada T, Mitsuhashi T, Shirota K, Kumagai K, Nuruki N, Shiraishi T, Nitta J, Ito H (2003) AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation. Pacing Clin Electrophysiol 26:1212–1217PubMedCrossRef Takahashi Y, Yoshito I, Takahashi A, Harada T, Mitsuhashi T, Shirota K, Kumagai K, Nuruki N, Shiraishi T, Nitta J, Ito H (2003) AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation. Pacing Clin Electrophysiol 26:1212–1217PubMedCrossRef
5.
Zurück zum Zitat Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M (2003) The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 41:1697–1702PubMedCrossRef Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M (2003) The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 41:1697–1702PubMedCrossRef
6.
Zurück zum Zitat Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK (2001) Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 344:1043–1051PubMedCrossRef Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK (2001) Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 344:1043–1051PubMedCrossRef
7.
Zurück zum Zitat Tan ES, Rienstra M, Wiesfeld AC, Schoonderwoerd BA, Hobbel HH, Van Gelder IC (2008) Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. Europace 10:412–418PubMedCrossRef Tan ES, Rienstra M, Wiesfeld AC, Schoonderwoerd BA, Hobbel HH, Van Gelder IC (2008) Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. Europace 10:412–418PubMedCrossRef
8.
Zurück zum Zitat Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ (2006) Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 48:1642–1648PubMedCrossRef Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ (2006) Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 48:1642–1648PubMedCrossRef
9.
Zurück zum Zitat Vernooy K, Dijkman B, Cheriex EC, Prinzen FW, Crijns HJ (2006) Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol 97:1223–1227PubMedCrossRef Vernooy K, Dijkman B, Cheriex EC, Prinzen FW, Crijns HJ (2006) Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol 97:1223–1227PubMedCrossRef
10.
Zurück zum Zitat Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S, Girardot R, Crepin D, Reant P, Roudaut R, Jaïs P, Haïssaguerre M, Clementy J, Jimenez M (2004) Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 110:3766–3772PubMedCrossRef Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S, Girardot R, Crepin D, Reant P, Roudaut R, Jaïs P, Haïssaguerre M, Clementy J, Jimenez M (2004) Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 110:3766–3772PubMedCrossRef
11.
Zurück zum Zitat Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932–2937PubMedCrossRef Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932–2937PubMedCrossRef
12.
Zurück zum Zitat Willems R, Wyse DG, Gillis AM (2003) Total atrioventricular nodal ablation increases atrial fibrillation burden in patients with paroxysmal atrial fibrillation despite continuation of antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 14:1296–1301PubMedCrossRef Willems R, Wyse DG, Gillis AM (2003) Total atrioventricular nodal ablation increases atrial fibrillation burden in patients with paroxysmal atrial fibrillation despite continuation of antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 14:1296–1301PubMedCrossRef
13.
Zurück zum Zitat Middlekauff HR, Stevenson WG, Stevenson LW (1991) Prognostic significance of atrial fibrillation in advanced heart failure. Circulation 84:40–48PubMedCrossRef Middlekauff HR, Stevenson WG, Stevenson LW (1991) Prognostic significance of atrial fibrillation in advanced heart failure. Circulation 84:40–48PubMedCrossRef
14.
Zurück zum Zitat Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925PubMedCrossRef Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925PubMedCrossRef
15.
Zurück zum Zitat ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117
16.
Zurück zum Zitat Buck T, Breithardt OA, Faber L, Fehske W, Flachskampf FA, Franke A, Hagendorff A, Hoffmann R, Kruck I, Kücherer H, Menzel T, Pethig K, Tiemann K, Voigt JU, Weidemann F, Nixdorff U (2009) Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol 4(Suppl 1):3–51 Buck T, Breithardt OA, Faber L, Fehske W, Flachskampf FA, Franke A, Hagendorff A, Hoffmann R, Kruck I, Kücherer H, Menzel T, Pethig K, Tiemann K, Voigt JU, Weidemann F, Nixdorff U (2009) Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol 4(Suppl 1):3–51
17.
Zurück zum Zitat Olgin JE, Scheinman MM (1993) Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 21:557–564PubMedCrossRef Olgin JE, Scheinman MM (1993) Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 21:557–564PubMedCrossRef
18.
Zurück zum Zitat Geelen P, Brugada J, Andries E, Brugada P (1997) Ventricular fibrillation and sudden cardiac death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 20:343–348PubMedCrossRef Geelen P, Brugada J, Andries E, Brugada P (1997) Ventricular fibrillation and sudden cardiac death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 20:343–348PubMedCrossRef
19.
Zurück zum Zitat Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997–2004 Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997–2004
20.
Zurück zum Zitat Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L (2009) A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11:676–683 Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L (2009) A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11:676–683
21.
Zurück zum Zitat Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA (2005) Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 45:82–86PubMedCrossRef Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA (2005) Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 45:82–86PubMedCrossRef
22.
Zurück zum Zitat Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the cardiovascular health study. Circulation 120:1768–1774PubMedCrossRef Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the cardiovascular health study. Circulation 120:1768–1774PubMedCrossRef
23.
Zurück zum Zitat Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127PubMedCrossRef Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127PubMedCrossRef
24.
Zurück zum Zitat Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C (2006) Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 29:559–563PubMedCrossRef Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C (2006) Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 29:559–563PubMedCrossRef
25.
Zurück zum Zitat Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6:92–96PubMedCrossRef Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6:92–96PubMedCrossRef
26.
Zurück zum Zitat Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van Den Berg MP, Driessen C, Grandjean JG, Van Gilst WH, Crijns HJ (1999) Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 10:827–835PubMedCrossRef Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van Den Berg MP, Driessen C, Grandjean JG, Van Gilst WH, Crijns HJ (1999) Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 10:827–835PubMedCrossRef
27.
Zurück zum Zitat Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié JL, Scavée C, Bordachar P, Clémenty J, Haïssaguerre M (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373–2383PubMedCrossRef Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié JL, Scavée C, Bordachar P, Clémenty J, Haïssaguerre M (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373–2383PubMedCrossRef
28.
Zurück zum Zitat Hagens VE, Crijns HJ, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV, Bosker HA, Kamp O, Tijssen JG, Veeger NJ, Van Gelder IC (2005) Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 149:1106–1111PubMedCrossRef Hagens VE, Crijns HJ, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV, Bosker HA, Kamp O, Tijssen JG, Veeger NJ, Van Gelder IC (2005) Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 149:1106–1111PubMedCrossRef
29.
Zurück zum Zitat Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2777PubMedCrossRef Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2777PubMedCrossRef
30.
Zurück zum Zitat Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA (2005) Left ventricular-based cardiac stimulation post AV nodal ablation evaluation. J Cardiovasc Electrophysiol 16:1160–1165PubMedCrossRef Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA (2005) Left ventricular-based cardiac stimulation post AV nodal ablation evaluation. J Cardiovasc Electrophysiol 16:1160–1165PubMedCrossRef
31.
Zurück zum Zitat Funck RC, Blanc JJ, Mueller HH, Schade-Brittinger C, Bailleul C, Maisch B (2006) Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the ‘Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace) study. Europace 8:629–635PubMedCrossRef Funck RC, Blanc JJ, Mueller HH, Schade-Brittinger C, Bailleul C, Maisch B (2006) Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the ‘Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace) study. Europace 8:629–635PubMedCrossRef
32.
Zurück zum Zitat De Teresa E, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Navarro X, Navarro-López F, Stockburger M (2007) Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: rationale and design of the PREVENT-HF study. Europace 9:442–446PubMedCrossRef De Teresa E, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Navarro X, Navarro-López F, Stockburger M (2007) Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: rationale and design of the PREVENT-HF study. Europace 9:442–446PubMedCrossRef
33.
Zurück zum Zitat Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Düngen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuss G, Pieske BM, Wachter R (2011) Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100:755–764PubMedCrossRef Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Düngen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuss G, Pieske BM, Wachter R (2011) Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100:755–764PubMedCrossRef
34.
Zurück zum Zitat Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19PubMedCrossRef Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19PubMedCrossRef
Metadaten
Titel
Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block
verfasst von
Brigitte Lampe
Christoph Hammerstingl
Jörg Otto Schwab
Fritz Mellert
Birgit Stoffel-Wagner
Andreas Grigull
Rolf Fimmers
Bernhard Maisch
Georg Nickenig
Thorsten Lewalter
Alexander Yang
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 10/2012
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-012-0468-7

Weitere Artikel der Ausgabe 10/2012

Clinical Research in Cardiology 10/2012 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.